Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Authors:
- Felix JohnFJFelix John
- Lea RugeLRLea Ruge
- Malte VerheyenMVMalte Verheyen
- Heather ScharpenseelHSHeather Scharpenseel
- Sebastian Yves Friedrich MichelsSMSebastian Yves Friedrich Michels
- Richard RiedelRRRichard Riedel
- Rieke FischerRFRieke Fischer
- Carolin JakobCJCarolin Jakob
- Janna Siemanowski-HrachJSJanna Siemanowski-Hrach
- Jana FassunkeJFJana Fassunke
- Carina HeydtCHCarina Heydt
- Michaela Angelika IhleMIMichaela Angelika Ihle
- 19 December 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 2110-2119
Abstract
Purpose: KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood. Experimental Design: In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed. Results: The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months. Conclusions: KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialJournal of Thoracic Oncology, 2024
- Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerJournal of Thoracic Oncology, 2023
- Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysisThe Lancet Regional Health - Europe, 2023
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerAnnals of Oncology, 2022
- Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of ImmunotherapyJournal of Thoracic Oncology, 2021
- KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancerCell Biology International, 2020
- Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%Annals of Oncology, 2020
- The current understanding of KRAS protein structure and dynamicsComputational and Structural Biotechnology Journal, 2020
- Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional TreatmentsJournal of Thoracic Oncology, 2019
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysJournal of Thoracic Oncology, 2019